Amalgamated Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Amalgamated Financial’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$68K	Buy	+16,235	New	+$71.9K	﹤0.01%	2277

Other funds holding AMRX

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's AMRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Amneal Pharmaceuticals (AMRX) in Q1 2022: 16,235 shares worth $68K. The stake represents ﹤0.01% of the portfolio and ranks #2277 among its holdings.

168 funds tracked by Wall St. Rank hold AMRX as of Q1 2022.

Amalgamated Financial held 16,235 shares of Amneal Pharmaceuticals worth $68K as of Q1 2022.
Amneal Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Amneal Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2277 holding.
168 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.